Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 500.00K | 500.00K | 500.00K | Gross Profit |
0.00 | -720.00K | -231.63K | -202.92K | -10.84M | EBIT |
-19.13B | -21.03M | -24.92M | -21.01M | -18.49M | EBITDA |
-19.13B | -19.88M | -31.71M | -20.88M | -21.30M | Net Income Common Stockholders |
-18.62B | -19.51M | -35.90M | -20.77M | -21.48M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
5.87M | 15.70M | 32.88M | 49.50M | 17.16M | Total Assets |
9.72M | 21.92M | 43.98M | 74.05M | 37.53M | Total Debt |
1.14B | 1.62M | 6.27M | 6.63M | 6.19M | Net Debt |
1.14B | -4.21M | -5.23M | -12.95M | -10.97M | Total Liabilities |
5.47M | 8.53M | 14.65M | 18.25M | 18.92M | Stockholders Equity |
4.24B | 13.39M | 29.33M | 55.80M | 18.61M |
Cash Flow | Free Cash Flow | |||
-18.88B | -19.47M | -23.40M | -16.54M | -15.64M | Operating Cash Flow |
-18.85B | -19.02M | -23.13M | -16.22M | -15.62M | Investing Cash Flow |
9.83B | 11.01M | 8.32M | -30.12M | 7.92M | Financing Cash Flow |
9.06B | -3.64M | 6.72M | 54.77M | 17.98M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $682.21M | ― | -37.72% | ― | ― | -3.08% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
42 Neutral | $15.42M | ― | -211.21% | ― | ― | 24.16% | |
36 Underperform | $98.19M | ― | -424.44% | ― | ― | 51.02% | |
32 Underperform | $69.25M | ― | -23.98% | ― | ― | -19.93% | |
30 Underperform | $65.31M | ― | 78.44% | ― | ― | ― |
On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.